glp-1 cv outcome trials receptor agonists were developed for glycemic control. The cardiovascular data has since reframed how cardiologists need to think about this drug class entirely. Across LEADER, SUSTAIN-6, REWIND, and SELECT, GLP-1 ✨ GLP-1 RAs: Cardiovascular Outcome
Pay in 4 interest-free payments of $6.06 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29

















:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)





